Allosteric CB1 ligands reduced eye pain and inflammation in a mouse corneal injury model | Research

The takeaway

Novel compounds that modulate CB1 receptors through an allosteric site reduced pain responses and inflammation in mice with corneal injuries.

Researchers studying cannabinoid pharmacology, ophthalmologists interested in novel pain treatments, and scientists working on allosteric modulator development.

Allosteric ligands enabled pain relief at subthreshold THC doses

What the researchers found

The CB1 allosteric ligand GAT228 reduced pain on its own, while GAT229 and GAT211 reduced pain when combined with a low dose of THC. Both GAT228 alone and GAT229 with THC also reduced corneal inflammation. Effects were blocked by a CB1 antagonist but persisted in CB2 knockout mice.

Why it matters

Current eye pain treatments have significant limitations. Allosteric modulators could enhance the therapeutic effects of cannabinoids at lower doses while potentially reducing side effects associated with direct CB1 activation.

The numbers in context

GAT228 at 2% concentration reduced pain scores. Combination of 0.5% GAT229 with 0.4% delta-8-THC significantly reduced pain. The 0.4% THC dose alone was subthreshold (inactive).

How the study worked

Corneal hyperalgesia was induced by chemical cauterization in wildtype and CB2 knockout mice. Pain was assessed after capsaicin stimulation at 6 hours post-injury. Novel allosteric CB1 ligands were tested alone and in combination with delta-8-THC.

What this study cannot tell us

Animal study using a mouse model of corneal injury. Pain assessment relied on behavioral scoring. No human data on safety, tolerability, or efficacy of these compounds.

How to read the evidence

Preclinical animal study demonstrating proof of concept. No human data available.

When this study was published

2020 animal study. Early-stage research into allosteric CB1 modulation for ocular pain.

The bigger picture

Allosteric modulators represent a newer approach to cannabinoid pharmacology. By fine-tuning receptor activity rather than fully activating it, these compounds may offer therapeutic benefits with fewer unwanted effects.

Questions still open

Would these allosteric ligands be safe and effective in human eyes? Could this approach work for other types of ocular conditions? What is the optimal ratio of allosteric modulator to THC for pain relief?

Common questions

What is an allosteric ligand?

An allosteric ligand binds to a different site on a receptor than the primary (orthosteric) binding site. It can modulate the receptor's response to other compounds without directly activating or blocking it in the same way.

Why combine allosteric modulators with THC?

The allosteric modulators enhanced THC's effects, allowing pain relief at doses of THC that were too low to work on their own. This could mean therapeutic benefits with fewer side effects.

Read the original research

Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.

Molecules (Basel, Switzerland), 25(2)

View on PubMed ↗Publisher’s paper ↗

Citation

Thapa, Dinesh; Cairns, Elizabeth A; Szczesniak, Anna-Maria; Kulkarni, Pushkar M; Straiker, Alex J; Thakur, Ganesh A; Kelly, Melanie E M. (2020). Allosteric Cannabinoid Receptor 1 (CB1) Ligands Reduce Ocular Pain and Inflammation.. Molecules (Basel, Switzerland), 25(2). https://doi.org/10.3390/molecules25020417